10
Journal of Chemistry
[14] H.-K. Han and G. L. Amidon, “Targeted prodrug design to
optimize drug delivery,” AAPS Pharmaceutical Sciences, vol. 2,
no. 1, p. E6, 2000.
Acknowledgments
ꢀis research was funded by Duy Tan University, Da Nang
city, Vietnam, and Vietnam National Foundation for Sci-
ence and Technology Development (NAFOSTED) under
grant no. 104.05-2019.03.
ˇ
ˇ
[15] R. Cizma´rikova´, S. Chuda´cˇikova´, J. Valentova´, and
´
A. Nemethy, “Synthesis and enantioseparation of derivatives
of propranolol,” Acta Facultatis Pharmaceuticae Universitatis
Comenianae, vol. 59, no. 1, pp. 5–13, 2012.
[16] M. N. Lokhande, M. U. Chopade, D. N. Bhangare, and
M. D. Nikalje, “Asymmetric synthesis of propranolol, naf-
topidil and (R)-monobutyrin using a glycerol desymmetri-
zation strategy,” Journal of the Brazilian Chemical Society,
vol. 24, pp. 406–409, 2013.
[17] J.-M. Hwang, T. Oh, and T. Kaneko, “Design, synthesis, and
structure–activity relationship studies of tryptanthrins as
antitubercular agents,” Journal of Natural Products, vol. 76,
no. 3, pp. 354–367, 2013.
[18] Y. L. N. Murthy, B. S. Diwakar, B. Govindh, R. Venu, and
K. Nagalakshmi, “Silica perchloric acid matrix supported ring
opening of epoxide under microwave radiation,” Chemical
Science Transactions, vol. 2, no. 3, pp. 805–812, 2013.
[19] P. Siengalewicz, J. Mulzer, and U. Rinner, “6.09 synthesis of
esters and lactones,” in Comprehensive Organic Synthesis II,
P. Knochel, Ed., pp. 355–410, Elsevier, Amsterdam, Nether-
lands, Second edition, 2014.
[20] M. Jia, L. Jiang, F. Niu, Y. Zhang, and X. Sun, “A novel and
highly efficient esterification process using triphenylphos-
phine oxide with oxalyl chloride,” Royal Society Open Science,
vol. 55, no. 5, Article ID 171988, 2018.
References
[1] S. Hardison, W. Wan, and K. M. Dodson, “ꢀe use of pro-
pranolol in the treatment of subglottic hemangiomas: a lit-
erature review and meta-analysis,” International Journal of
Pediatric Otorhinolaryngology, vol. 90, pp. 175–180, 2016.
[2] S. A. Steenen, A. J. Van Wijk, G. J. Van der Heijden,
R. Van Westrhenen, J. De Lange, and A. De Jongh, “Pro-
pranolol for the treatment of anxiety disorders: systematic
review and meta-analysis,” Journal of Psychopharmacology
(Oxford, England), vol. 30, no. 2, pp. 128–139, 2016.
[3] A. V. Srinivasan, “Propranolol: a 50-year historical per-
spective,” Annals of Indian Academy of Neurology, vol. 22,
no. 1, pp. 21–26, 2019.
ˇ
ˇ
[4] R. Cizma´rikova´, L. Habala, J. Valentova´, and M. Markuliak,
“Survey of pharmacological activity and pharmacokinetics of
selected β-adrenergic blockers in regard to their stereo-
chemistry,” Applied Sciences, vol. 9, no. 4, p. 625, 2019.
[5] W. H. Frishman, “Beta-adrenergic receptor blockers in hy-
pertension: alive and well,” Progress in Cardiovascular Dis-
eases, vol. 59, no. 3, pp. 247–252, 2016.
[21] F. A. Luzzio, R. W. Fitch, W. J. Moore, and K. J. Mudd, “A
facile oxidation of alcohols using pyridinium chlorochromate/
silica gel,” Journal of Chemical Education, vol. 76, no. 7, p. 974,
1999.
[6] P.-Y. Chang, W.-Y. Huang, C.-L. Lin et al., “Propranolol
reduces cancer risk: a population-based cohort study,”
Medicine, vol. 94, no. 27, Article ID e1097, 2015.
[7] E. M. Yee, E. Pasquier, G. Iskander, K. Wood, D. S. Black, and
N. Kumar, “Synthesis of novel isoflavene-propranolol hybrids
as anti-tumor agents,” Bioorganic & Medicinal Chemistry,
vol. 21, no. 7, pp. 1652–1660, 2013.
[22] W. S. Emerson, )e Preparation of amines by reductive al-
kylation, Organic Reactions, pp. 174–255, 2011.
[8] S. Batra and R. Bhushan, “Methods and approaches for de-
termination and enantioseparation of (RS)-propranolol,”
Biomedical Chromatography, vol. 33, no. 1, Article ID e4370,
2019.
[9] M. Sasaki, P. E. North, J. Elsey et al., “Propranolol exhibits
activity against hemangiomas independent of beta blockade,”
Npj Precision Oncology, vol. 3, no. 1, p. 27, 2019.
[10] N. Singh, A. Kumar, and R. Singh, “Concise synthesis of (S)-
(-)-propranolol: using acid catalysed kinetic resolution,”
Journal of Chemical and Pharmaceutical Research, vol. 4,
no. 12, pp. 5111–5113, 2012.
[11] X. Wu, A. Noda, H. Noda, and Y. Imamura, “Side-chain
metabolism of propranolol: involvement of monoamine ox-
idase and aldehyde reductase in the metabolism of N-desi-
sopropylpropranolol to propranolol glycol in rat liver,
Comparative biochemistry and physiology,” Toxicology &
Pharmacology: CBP, vol. 129, no. 4, pp. 361–368, 2001.
[12] A. Gharib, M. Jahangir, and M. Roshani, “Synthesis of (S)-
(-)-Propranolol by using Cs2.5H0.5PW12O40 nanocatalyst as
green, eco-friendly, reusable, and recyclable catalyst, synthesis
and reactivity in inorganic, metal-organic,” Synthesis and
Reactivity in Inorganic, Metal-Organic, and Nano-Metal
Chemistry, vol. 45, no. 3, pp. 350–355, 2015.
[13] S. A. M. Yassin and K. F.-A. Samarrai, “Ratio spectrum de-
rivative quantitative analysis of propranolol and diazipam in
combind pharmaceutical mixtures,” International Journal of
Research in Pharmaceutical Sciences, vol. 10, no. 4,
pp. 3657–3664, 2019.